Up to
Long-Acting Medicines
That Fit Real Life
Latest news & events
Degroof Petercam Initiates Medincell’s Coverage with a “Buy” Recommendation
Degroof Petercam Initiates Medincell’s Coverage with a “Buy” Recommendation
Leerink Partners Initiates Medincell’s Coverage with a “Outperform” Recommendation
Leerink Partners Initiates Medincell’s Coverage with a “Outperform” Recommendation
Medincell to Host an online R&D Day on Tuesday, May 12, 2026
Medincell to Host an online R&D Day on Tuesday, May 12, 2026
EIB Waives its Right to Cash Settlement on Medincell Warrants
EIB Waives its Right to Cash Settlement on Medincell Warrants
80%
%
of patients discontinue long‑term treatments over time.
Addressing a major global challenge
By reducing dosing frequency, LAIs can help ensure adherence, a key driver of real‑world treatments effectiveness.
Long-Acting Innovation
Our technologies enable a long‑acting injectable alternative to daily oral treatments, delivering sustained therapeutic levels for days, weeks, or months.
Unlocking LAIs in Psychiatry
Our two first products on the market and soon to be on the market are targeting therapeutic areas where adherence is critical: Schizophrenia and Bipolar disorder, two diseases where LAIs can drastically change lives of patients.
UZEDY®, our first, innovative treatments enabled by our technology, co‑developed with top‑tier partner, already benefit thousands of patients worldwide.
Our Pipeline
Internal and partner programs, adressing many TAs where LAIs can fill an unmet need. We also support Global Health programs through foundation sponsoring.
Our pipeline goes from formulation to Phase III Clinical.
You are
Join the team
Unleash your entrepreneurial spirit within a creative and innovative team of international experts dedicated to tackling global health challenges.
Strategy, pipeline and outlook
Corporate Presentation
Get in touch
Please use the form for any inquiries. We’ll get back to you promptly.
